Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

NCT03232567 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Altimmune, Inc.